View More View Less
  • 1 Országos Onkológiai Intézet, Budapest
  • | 2 Szegedi Tudományegyetem, Szeged
  • | 3 Petz Aladár Megyei Kórház, Győr
  • | 4 Semmelweis Egyetem, Budapest
  • | 5 Szt. Margit Kórház, Budapest
  • | 6 Megyei Kórház, Kecskemét
  • | 7 Veszprém Megyei Csolnoky Ferenc Kórház, Veszprém
  • | 8 Pándy Kálmán Kórház, Gyula
Restricted access
  • 1. K Liang Y Lu W Jin et al.2003 Sensitization of breast cancer cells to radiation by trastuzumab Mol Cancer Ther 2 1113 1120.

  • 2. Slamon D , Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC'T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC'TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients: BCIRG 006 study. Cancer Res 69 (Suppl), San Antonio Breast Cancer Symposium 2009, abstr. no. 62.

    • Search Google Scholar
    • Export Citation
  • 3. B Fisher S Anderson DL Wickerham et al.1997 Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22 J Clin Oncol 15 1858 1869.

    • Search Google Scholar
    • Export Citation
  • 4. B Fisher AM Braun NV Dimitrov et al.1990 Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, fluorouracil in node-positive breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15 J Clin Oncol 8 1483 1496.

    • Search Google Scholar
    • Export Citation
  • 5. B Fisher S Anderson A DeCilis et al.1999 Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25 J Clin Oncol 17 3374 3388.

    • Search Google Scholar
    • Export Citation
  • 6. L Biganzoli T Zufer P Bruning et al.2002 Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicentre phase III trial J Clin Oncol 20 3114 3121.

    • Search Google Scholar
    • Export Citation
  • 7. J O'Shaughnessy 2003 Pegylated liposomal doxorubicin in the treatment of breast cancer Clin Breast Cancer 4 318 328.

  • 8. M O'Brien N Wigler M Inbar et al.2004 Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCI (Caelyx/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann Oncol 15 440 449.

    • Search Google Scholar
    • Export Citation
  • 9. C Pico M Martin C Jara et al.2004 Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study Ann Oncol 15 79 87.

    • Search Google Scholar
    • Export Citation
  • 10. M Martin A Villar A Sole-Calvo et al.2003 Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil, and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: A study by the GEICAM group Ann Oncol 14 833 842.

    • Search Google Scholar
    • Export Citation
  • 11. LF Hutchins SJ Green PM Ravdin et al.2005 Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: Treatment results of intergroup protocol INT-0102 J Clin Oncol 23 8313 8321.

    • Search Google Scholar
    • Export Citation
  • 12. C Blajman L Balbiani J Block et al.1999 A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma Cancer 85 1091 1097.

    • Search Google Scholar
    • Export Citation
  • 13. F Zhang Y Yang T Smith et al.2003 Correlation between HER-2-expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma Cancer 97 1758 1765.

    • Search Google Scholar
    • Export Citation
  • 14. French Adjuvant Study Group 2001 Benefit of high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial J Clin Oncol 19 602 611.

    • Search Google Scholar
    • Export Citation
  • 15. French Epirubicin Study Group 2000 Epirubicin-based chemotherapy in metastatic breast cancer patients: Role of dose-intensity and duration of treatment J Clin Oncol 18 3115 3124.

    • Search Google Scholar
    • Export Citation
  • 16. P Fumoleau P Kerbrat P Romestaing et al.2003 Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial J Clin Oncol 21 298 305.

    • Search Google Scholar
    • Export Citation
  • 17. JA van der Hage C van de Velde JP Julian et al.2001 Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902 J Clin Oncol 19 4224 4237.

    • Search Google Scholar
    • Export Citation
  • 18. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: five-year follow-up results of FASG 05 randomized trial. J Clin Oncol 18: 602611, 2001.

    • Search Google Scholar
    • Export Citation
  • 19. J Bonneterre H Roche P Kerbrat et al.2005 Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial J Clin Oncol 23 2686 2693.

    • Search Google Scholar
    • Export Citation
  • 20. MN Levine V Bramwell K Pritchard 1998 Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer J Clin Oncol 16 2651 2658.

    • Search Google Scholar
    • Export Citation
  • 21. MN Levine KI Pritchard VHC Bramwell et al.2005 Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5 J Clin Oncol 23 5166 5170.

    • Search Google Scholar
    • Export Citation
  • 22. J Bergh T Wiklund B Eikstein et al.2000 Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial – Scandinavian Breast Group 9401 study Lancet 356 1384 1391.

    • Search Google Scholar
    • Export Citation
  • 23. EA Perez C Vogel D Irwin et al.2001 Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer J Clin Oncol 19 4216 4223.

    • Search Google Scholar
    • Export Citation
  • 24. K Friedrichs F Hölzel F Janiocke et al.2002 Combinations of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report Eur J Cancer 38 1730 1738.

    • Search Google Scholar
    • Export Citation
  • 25. JM Nabholtz C Falkson D Campos et al.2003 Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial J Clin Oncol 21 968 975.

    • Search Google Scholar
    • Export Citation
  • 26. E Alba M Martin M Ramos et al.2004 Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study J Clin Oncol 22 2587 2593.

    • Search Google Scholar
    • Export Citation
  • 27. JM Nabholtz D Reese MA Lindsay et al.2002 Docetaxel in the treatment of breast cancer: an update on recent studies Semin Oncol 29(Suppl 12) 28 34.

    • Search Google Scholar
    • Export Citation
  • 28. Martin M , Pienkowski T, Mackey J, et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Breast Cancer Res Treat 82 (Suppl 1), San Antonio Breast Cancer Symposium, 2003.

    • Search Google Scholar
    • Export Citation
  • 29. HD Bear AS Anderson A Brown et al.2003 The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project protocol B-27 J Clin Oncol 21 4165 4174.

    • Search Google Scholar
    • Export Citation
  • 30. IC Henderson DA Berry GD Demetri et al.2003 Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer J Clin Oncol 21 976 983.

    • Search Google Scholar
    • Export Citation
  • 31. ML Citron D Berry C Cirrincione et al.2003 Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741 / Cancer and Leukemia Group B trial 9741 J Clin Oncol 21 1431 1439.

    • Search Google Scholar
    • Export Citation
  • 32. Sparano JA , Wang M, Martino S, et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. San Antonio Breast Cancer Symposium, 2005, abstr. no. 48.

    • Search Google Scholar
    • Export Citation
  • 33. Jones SE , Savin MA, Holmes FA, et al. Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer. San Antonio Breast Cancer Symposium, 2005, abstr. no. 40.

    • Search Google Scholar
    • Export Citation
  • 34. Goldstein L , O'Neill A, Sparano J, Perez E. E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/ cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. ASCO Annual Meeting Proceedings, 2005, abstr. no. 512.

    • Search Google Scholar
    • Export Citation
  • 35. G Bonadonna E Brusamolino P Valagussa et al.1976 Combination chemotherapy as an adjuvant treatment in operable breast cancer N Engl J Med 294 405 410.

    • Search Google Scholar
    • Export Citation
  • 36. M Colleoni K Pritce M Kastiglione-Gertsch et al.1998 Dose response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer Eur J Cancer 34 1693 1700.

    • Search Google Scholar
    • Export Citation
  • 37. E Engelsman JCM Klijn RD Rubens et al.1991 Classical CMF versus 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group phase III trial (10808) Eur J Cancer 27 966 970.

    • Search Google Scholar
    • Export Citation
  • 38. Roche H , Fumoleau P, Spielmann M. Five years analysis of the PACS 01 trial: 6 cycles of FEC 100 vs 3 dycles of FEC 100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium, 2004, abstr. no. 27.

    • Search Google Scholar
    • Export Citation
  • 39. Martín M , Rodríguez-Lescure A, Ruiz A, et al. Multicenter, randomized phase III study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FE90C versus 4 cycles of FE90C followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. San Antonio Breast Cancer Symposium, 2005, abstr. no. 39.

    • Search Google Scholar
    • Export Citation
  • 40. J O'Shaughnessy d Miles S Vukelja et al.2002 Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J Clin Oncol 20 2812 2823.

    • Search Google Scholar
    • Export Citation
  • 41. Genot JY. Gemcitabine and paclitaxel in metastatic breast cancer: a phase II study in the first-line setting. Proc Am Soc Clin Oncol 21: abstract, 2002.

    • Search Google Scholar
    • Export Citation
  • 42. JM Extra F Cognetti S Chan et al.2003 Randomized phase II trial (M77001) of trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastatic breast cancer Eur J Cancer 1(Suppl 5) 202.

    • Search Google Scholar
    • Export Citation
  • 43. HJ Burstein L Harris K Marcom et al.2003 Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm J Clin Oncol 21 2889 2895.

    • Search Google Scholar
    • Export Citation
  • 44. HJ Lück H Roche 2002 Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer Crit Rev Oncol Hematol 44(Suppl 1) S15 S30.

    • Search Google Scholar
    • Export Citation
  • 45. C Bernard-Marty F Cardoso MJ Piccart et al.2003 Use and abuse of taxanes in the management of metastatic breast cancer Eur J Cancer 39 1978 1989.

    • Search Google Scholar
    • Export Citation
  • 46. JM Nabholtz K Gelmon M Bontenbal et al.1997 Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer J Clin Oncol 14 1858 1867.

    • Search Google Scholar
    • Export Citation
  • 47. R Paridaens L Biganzoli P Bruning et al.2000 Paclitaxel versus doxorubicin as 1st-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over J Clin Oncol 18 724 733.

    • Search Google Scholar
    • Export Citation
  • 48. GW Sledge D Neuberg P Bernardo et al.2003 Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) J Clin Oncol 21 588 592.

    • Search Google Scholar
    • Export Citation
  • 49. EP Winer D Berry S Woolf et al.2004 Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342 J Clin Oncol 22 2061 2068.

    • Search Google Scholar
    • Export Citation
  • 50. HJ Burstein J Manola J Younger et al.2000 Docetaxel administered on a weekly basis for metastatic breast cancer J Clin Oncol 18 1212 1219.

    • Search Google Scholar
    • Export Citation
  • 51. J Bonneterre H Roche A Monnier et al.2002 Docetaxel vs. 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure Br J Cancer 87 1210 1215.

    • Search Google Scholar
    • Export Citation
  • 52. S Chan K Fiedrichs D Noel et al.1999 Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer J Clin Oncol 17 2341 2354.

    • Search Google Scholar
    • Export Citation
  • 53. JM Nabholtz HJ Senn WR Bezwoda et al.1999 Prospective trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy J Clin Oncol 17 1413 1424.

    • Search Google Scholar
    • Export Citation
  • 54. E Salminen M Bergman S Uhtala et al.1999 Docetaxel: standard recommended dose of 100 mg/m≈ is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy – A phase II single-center study J Clin Oncol 17 1127 1131.

    • Search Google Scholar
    • Export Citation
  • 55. J Sjöström C Blomqvist H Mouridsen et al.1999 Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group Eur J Cancer 35 1194 1201.

    • Search Google Scholar
    • Export Citation
  • 56. VG Kaklamani WJ Gradishar 2003 Role of capecitabine (Xeloda®) in breast cancer Exp Rev Anticancer Ther 3 137 144.

  • 57. J O'Shaughnessy 2002 Clinical experience of capecitabine in metastatic breast cancer Eur J Cancer 38(Suppl) 10 14.

  • 58. M Spielmann A Llombart-Cussac S Kalla et al.2001 Single-agent gemcitabine is active in previously treated metastatic breast cancer Oncology 60 303 307.

    • Search Google Scholar
    • Export Citation
  • 59. J Garcia-Coude A Lluch M Martin et al.1994 Phase II trial of weekly vinorelbine in first-line advanced breast cancer chemotherapy Ann Oncol 5 854 957.

    • Search Google Scholar
    • Export Citation
  • 60. SC Twelves NA Dobbs A Curnow et al.1994 A phase II, multicenter UK study of vinorelbine in advanced breast cancer Br J Cancer 70 990 993.

    • Search Google Scholar
    • Export Citation
  • 61. CL Vogel M O'Rourke E Winer et al.1999 Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years old Ann Oncol 10 397 402.

    • Search Google Scholar
    • Export Citation
  • 62. BL Weber CL Vogel S Jones et al.1995 Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer J Clin Oncol 13 2722 2730.

    • Search Google Scholar
    • Export Citation
  • 63. G Freyer T Delozier M Lichinister et al.2003 Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy J Clin Oncol 21 35 40.

    • Search Google Scholar
    • Export Citation
  • 64. H Mouridsen C Rose MA Nooy et al.1983 Mitoxantrone as first line cytotoxic therapy in advanced breast cancer: Preliminary results of a phase II study Cancer Treat Rev 10(Suppl B) 47 52.

    • Search Google Scholar
    • Export Citation
  • 65. MA Cobleigh CL Vogel D Tripathy et al.1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639 2648.

    • Search Google Scholar
    • Export Citation
  • 66. CL Vogel M Cobleigh D Tripathy et al.2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719 726.

    • Search Google Scholar
    • Export Citation

Magyar Onkológia
Language Hungarian
Size  
Year of
Foundation
1956
Publication
Programme
 
Volumes
per Year
 
Issues
per Year
 
Founder Magyar Onkológusok Társasága
Founder's
Address
H-1122 Budapest, Hungary Ráth György u. 7-9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 0025-0244 (Print)
ISSN 2060-0399 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Apr 2021 5 0 0
May 2021 7 0 0
Jun 2021 10 0 0
Jul 2021 39 1 1
Aug 2021 61 5 6
Sep 2021 27 1 1
Oct 2021 0 0 0